Free Webex Call
The Global Autoimmune Disease Diagnostics Market was valued at USD 5.02 Billion in 2022 and is expected to exhibit strong growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.37% and expected to reach USD 7.28 Billion through 2028. Autoimmune disease (AD) is a non-communicable ailment characterized by the disruption of healthy immunological equilibrium, leading to aberrant reactions in affected tissue cells. Inflammation, autoantibodies, and activated T cells are pivotal in the development of autoimmune disorders. While immune cells typically recognize and combat external agents like bacteria and viruses, autoimmune diseases lead to the immune system erroneously attacking the body itself. Some autoimmune conditions specifically target particular organs. Globally, almost 80 types of autoimmune diseases exist, including systemic lupus erythematosus and rheumatoid arthritis. The American Autoimmune Related Diseases Association (AARDA) reveals that up to 50 million Americans suffer from autoimmune diseases, with females constituting 75% of the cases. Diagnostic tests for autoimmune diseases encompass autoantibody tests, antinuclear antibody tests, complete blood count, C-reactive protein, and erythrocyte sedimentation rate.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Market Drivers
Growing Awareness of Autoimmune Diseases
Stress, genetic mutations, unhealthy eating habits, and environmental factors contribute significantly to autoimmune disease development. The global prevalence of autoimmune diseases has led to an increased demand for autoimmune disease diagnostics. For instance, the 2020 CDC National Diabetes Statistics Report states that approximately 1.4 million Americans have Type-1 diabetes, with projections indicating a rise to 2.1 million by 2040. Heightened awareness efforts by public and private organizations have contributed to increased knowledge of autoimmune diseases. Organizations like the Autoimmune Association (U.S.) conduct awareness campaigns to disseminate information about these disorders. Early autoimmune disease diagnosis is pivotal in minimizing disability, morbidity, and mortality rates, driving the autoimmune disease diagnostics market's growth.Increasing Incidence of Autoimmune Diseases
The increasing prevalence of autoimmune diseases, such as Inflammatory Bowel Disease (IBD) and rheumatoid arthritis, is expected to significantly impact the autoimmune disease diagnostics market. As more individuals are affected, there is a greater emphasis on early detection and diagnosis. This timely diagnosis is crucial for initiating appropriate treatment and management strategies. The higher incidence of different autoimmune diseases necessitates a diverse array of diagnostic tests that can accurately differentiate between these conditions. These developments contribute to the demand for a comprehensive diagnostic toolkit to address diverse disease presentations.Improvement in Diagnostic Techniques
Technological advancements have enabled the simultaneous identification and measurement of multiple autoantibodies. Techniques like antigen microarrays and mass spectrometry offer increased sensitivity in detecting specific antibodies or biomarkers associated with autoimmune diseases. These advancements allow for more precise and early detection. Automation of laboratories and the replacement of conventional technologies contribute to the expansion of the global autoimmune disease diagnostics market.Key Market Challenges
Need for Multiple Diagnostic Tests and Prolonged Turnaround Time
Detecting autoimmune diseases is time-consuming, involving various testing scenarios like serum testing for rheumatoid arthritis, Addison's disease, and Hashimoto's disease. Multiple laboratory tests are necessary due to no single test reliably detecting a specific autoimmune disease with high accuracy. These tests may include a complete metabolic panel, blood count report, serologies, flow cytometry, and HLA typing. Turnaround times for these tests can be extended, impeding prompt diagnosis. Moreover, high test costs and reimbursement issues are challenges. The lack of skilled professionals also impacts the market.Limited Penetration in Developing Regions
While autoimmune diseases' prevalence is rising, limited product penetration restricts market expansion. Developing markets lack surveillance and databases for emerging diseases like IBD. Epidemiological data and access to efficient diagnostics are limited. Lack of awareness hampers appointments, impeding market growth in emerging countries.Key Market Trends
Innovative Autoimmune Disease Detection Approaches
The demand for accurate diagnosis fosters a competitive landscape, encouraging new players. Competitive pricing among established leaders is encouraged, and the Asia-Pacific region offers potential due to untapped growth and an expanding patient population. Research studies present revenue opportunities, and awareness efforts create room for unique diagnostic techniques' development. Automation and conventional technology replacement contribute to market expansion.Point-of-Care and Home Testing
Demand for convenient and rapid diagnostics could drive point-of-care and home testing kits' development. Patients can monitor their conditions conveniently, aiding quicker treatment decisions. Home testing reduces healthcare facility burden and allows patients to play a more active role in their healthcare.Segmental Insights
Disease Type
Localized disease diagnostics dominated the market due to large procedure volumes and relatively higher patient awareness. Systemic disease diagnostics are projected to grow rapidly, fueled by favorable government initiatives and increased awareness.Product
The reagents, assays, and kits segment is expected to hold the largest market share by 2023, driven by high diagnosis rates and recurring purchases in developed countries.Regional Insights
Asia-Pacific
The Asia-Pacific region is poised for high growth due to increasing autoimmune disease prevalence, unhealthy lifestyles, government initiatives, and research investments. Psoriasis cases in India are projected to rise, contributing to the region's growing prevalence.Conclusion
The Global Autoimmune Disease Diagnostics Market is experiencing growth due to rising awareness, increasing autoimmune disease incidence, diagnostic improvements, and innovative approaches. Challenges include the need for multiple tests, extended turnaround time, limited penetration in developing regions, and a shortage of skilled professionals. Trends include innovative detection methods and point-of-care/home testing. Disease type, product, and regional factors are influencing market dynamics. The Asia-Pacific region holds potential due to expanding autoimmune disease prevalence. Overall, the autoimmune disease diagnostics market is set to grow with a focus on early diagnosis and improved testing techniques.Key Market Players
- Siemens Healthcare Private Limited
- bioMérieux SA
- Bio-rad Laboratories
- Beckman Coulter, Inc.
- F. Hoffmann-la Roche
- Inova Diagnostics, Inc.
- Myriad Genetics, Inc.
- Thermo Fisher Scientific
- Trinity Biotech Plc.
- Hemagen Diagnostics, Inc.
Report Scope:
In this report, the Global Autoimmune Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Autoimmune Disease Diagnostics Market, By Product:
- Reagents
- Kits
- Assays
- Instruments
Autoimmune Disease Diagnostics Market, By Test Type:
- Antinuclear Antibody Tests
- Autoantibody Tests
- C-reactive Protein
- Complete Blood Count
- Urinalysis
Autoimmune Disease Diagnostics Market, By Disease Type:
- Systemic
- Localized
Autoimmune Disease Diagnostics Market, By End User:
- Hospitals
- Diagnostic Labs
- Research Institutes
Autoimmune Disease Diagnostics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Turkey
- Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Autoimmune Disease Diagnostics Market.Available Customizations:
Global Autoimmune Disease Diagnostics market report with the given market data, the publisher offers customizations according to a company's specific needs.This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview2. Research Methodology3. Executive Summary4. Voice of Customer11. Market Dynamics12. Market Trends & Developments13. Global Autoimmune Disease Diagnostics Market: SWOT Analysis15. Strategic Recommendations16. About the Publisher & Disclaimer
5. Global Autoimmune Disease Diagnostics Market Outlook
6. North America Autoimmune Disease Diagnostics Market Outlook
7. Europe Autoimmune Disease Diagnostics Market Outlook
8. Asia-Pacific Autoimmune Disease Diagnostics Market Outlook
9. South America Autoimmune Disease Diagnostics Market Outlook
10. Middle East and Africa Autoimmune Disease Diagnostics Market Outlook
14. Competitive Landscape
Companies Mentioned
- Siemens Healthcare Private Limited
- bioMérieux SA
- Bio-rad Laboratories
- Beckman Coulter, Inc.
- F. Hoffmann-la Roche
- Inova Diagnostics, Inc.
- Myriad Genetics, Inc.
- Thermo Fisher Scientific
- Trinity Biotech Plc.
- Hemagen Diagnostics, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 189 |
Published | October 2023 |
Forecast Period | 2023 - 2028 |
Estimated Market Value ( USD | $ 5.02 Billion |
Forecasted Market Value ( USD | $ 7.28 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |